- Home
- HOOK vs ATHA Comparison
HOOK vs ATHA Comparison
Compare HOOK & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- ATHA
- Stock Information
- Founded
- HOOK 2011
- ATHA 2011
- Country
- HOOK United States
- ATHA United States
- Employees
- HOOK N/A
- ATHA N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- HOOK Health Care
- ATHA Health Care
- Exchange
- HOOK Nasdaq
- ATHA Nasdaq
- Market Cap
- HOOK 9.3M
- ATHA 10.6M
- IPO Year
- HOOK 2019
- ATHA 2020
- Fundamental
- Price
- HOOK $1.25
- ATHA $0.31
- Analyst Decision
- HOOK Buy
- ATHA Buy
- Analyst Count
- HOOK 4
- ATHA 4
- Target Price
- HOOK $10.67
- ATHA $11.25
- AVG Volume (30 Days)
- HOOK 62.9K
- ATHA 1.3M
- Earning Date
- HOOK 08-07-2025
- ATHA 07-31-2025
- Dividend Yield
- HOOK N/A
- ATHA N/A
- EPS Growth
- HOOK N/A
- ATHA N/A
- EPS
- HOOK N/A
- ATHA N/A
- Revenue
- HOOK $9,351,000.00
- ATHA N/A
- Revenue This Year
- HOOK N/A
- ATHA N/A
- Revenue Next Year
- HOOK N/A
- ATHA N/A
- P/E Ratio
- HOOK N/A
- ATHA N/A
- Revenue Growth
- HOOK N/A
- ATHA N/A
- 52 Week Low
- HOOK $0.72
- ATHA $0.22
- 52 Week High
- HOOK $6.77
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- HOOK 38.94
- ATHA 49.52
- Support Level
- HOOK $1.23
- ATHA $0.29
- Resistance Level
- HOOK $1.30
- ATHA $0.35
- Average True Range (ATR)
- HOOK 0.06
- ATHA 0.03
- MACD
- HOOK -0.03
- ATHA -0.00
- Stochastic Oscillator
- HOOK 5.97
- ATHA 14.10
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.